Remix Therapeutics announced a collaboration and license agreement with Roche (RHHBY) for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform. Remix will receive an upfront payment of $30 million and are eligible to receive up to $12 million in near-term milestone payments, as well as milestones of up to $1 billion and tiered royalties.
Under the terms of the agreement, Roche will have exclusive rights to specific targets. Remix will conduct discovery and preclinical activities with Roche. Roche will be responsible for development and commercialization of any resulting products.
The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.